Please login to the form below

Not currently logged in
Email:
Password:

propofol

This page shows the latest propofol news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca sells rights to seven anaesthetics in $770m deal

AstraZeneca sells rights to seven anaesthetics in $770m deal

topical anaesthetics Diprivan (propofol) and EMLA (lidocain and prilocaine), plus five local anaesthetics.

Latest news

  • R&D news in brief

    SkyePharma and Endo halt Propofol IDD-DTM development. SkyePharma says it has agreed with US partner Endo to terminate joint development of Propofol IDD-DTM, an injectable anaesthetic and sedative that ... Under the terms of the December 2002 agreement,

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and Diprivan (propofol), a short acting intravenous sedative/ anaesthetic.

  • Pharma deals in February 2015 Pharma deals in February 2015

    The sedative and analgesic propofol recall on the very day the acquisition was announced due, and not for the first time, to particulate iron embedded in the neck of a vial

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics